Fig. 1: Tumor response in the modified intent-to-treat population. | Nature Communications

Fig. 1: Tumor response in the modified intent-to-treat population.

From: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

Fig. 1

Waterfall plot for best percent change in sum of diameters per RECIST (v1.1) by Dose (A) and PD-L1 (B) in the overall modified intent-to-treat (mITT) population; C Spider plot for percent change in sum of diameters by PD-L1 in the overall mITT population. Source data is provided in the source Data file.

Back to article page